MEDICATIONS

CagriSema

An investigational combination of cagrilintide and semaglutide that targets both amylin and GLP-1 pathways, producing greater weight loss than either medication alone.

CagriSema is an investigational weight loss medication that combines two active ingredients: cagrilintide and semaglutide. Cagrilintide mimics a fullness hormone called amylin, while semaglutide mimics GLP-1, a hormone that controls appetite and blood sugar. Together, they produce greater weight loss than either medication alone.

CagriSema is a fixed-dose combination of the long-acting amylin analogue cagrilintide (2.4 mg) and the GLP-1 receptor agonist semaglutide (2.4 mg), administered as a once-weekly subcutaneous injection. Phase 2 trial data (Lancet, 2024) demonstrated a mean weight loss of 15.6% from baseline at 32 weeks versus 5.1% for semaglutide alone. The dual mechanism — amylin-mediated satiety enhancement via hindbrain signalling plus GLP-1-mediated appetite suppression and delayed gastric emptying — addresses complementary pathways in energy homeostasis.

CagriSema represents the next generation of combination pharmacotherapy for obesity, potentially matching the weight loss achieved by some bariatric procedures without surgery. At NuLifeCare Singapore, Dr. Joseph Wang stays current with emerging treatments like CagriSema to offer you the most advanced options in medical weight management.

⚕️

Medical Disclaimer

This library is for general education and does not replace individual assessment by a qualified healthcare professional. Always consult a doctor for medical advice, diagnosis, or treatment.

← Back to Weight Management Library